This site is intended for healthcare professionals
Drug information

OTC
Read time: 1 mins
Last updated: 06 Sep 2021

Summary of product characteristics


1. Name of the medicinal product

Norgalax


2. Qualitative and quantitative composition

Norgalax contains the active ingredient Docusate Sodium 0.12 gin each 10g micro-enema.


3. Pharmaceutical form

Rectal gel.


4.1. Therapeutic indications

For the symptomatic treatment of constipation whenever an enema is required and for the preparation of the colon and rectum for endoscopic examination.


4.2. Posology and method of administration

Adults: use one micro-enema. If required, a second micro-enema may be used on the same or the next day.

Children:

not recommended for children under 12 years old.

Norgalax is to be administered rectally. Remove the protective cap and insert the applicator in to the rectum, squeezing gently until the tube is empty. A drop of the gel maybe used as a lubricant if required.


4.3. Contraindications

Haemorrhoids, anal fissures, rectocolitis, anal bleeding, abdominal pain, intestinal obstruction, nausea, vomiting, inflammatory bowel disease, ileus and known hypersensitivity to any of the ingredients.


4.4. Special warnings and precautions for use

As with all laxatives, Norgalax should not be administered chronically. Prolonged use can precipitate the onset of an atonic non- functioning colon and hypokalaemia.


4.5. Interaction with other medicinal products and other forms of interaction

Norgalax may increase the resorption of medicines and is not to be used in combination with hepatotoxic agents.


4.6. Fertility, pregnancy and lactation

Pregnancy

There are no adequate data from the use of docusate enema or oral docusate in pregnant women. Animal studies with oral docusate are insufficient with respect to effects on pregnancy and embryonic foetal development.

The potential risk for humans is unknown. As minimal systemic absorption cannot be ruled out following rectal application, Norgalax should be used in pregnancy only if the benefits outweigh the risks.

Lactation

It is unknown whether docusate is excreted in human breast milk. Animal studies have shown excretion of docusate and its metabolites in breast milk when administered systemically. A decision on whether to continue/discontinue breast-feeding or continue/discontinue therapy with NORGALAX should be made taking into account the benefit of breast-feeding to the child and the benefit of NORGALAX therapy to the woman.


4.7. Effects on ability to drive and use machines

None known.


4.8. Undesirable effects

Gastrointestinal disorders: anal burning, rectal pain, rectal bleeding, diarrhoea

Skindisorders: urticaria

Hepaticdisorders: cases of hepatotoxicity have been reported with oral intake of docusate taken together with other laxatives.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard.


4.9. Overdose

Overdose will lead to excessive purgation which should be treated symptomatically.


5.1. Pharmacodynamic properties

Docusatesodium is an anionic surfactant and used as a faecal softening agent. It is considered to ease constipation by increasing the penetration of fluid into the faeces thereby causing them to soften. Norgalax is usually effective in 5 to 20 minutes.


5.2. Pharmacokinetic properties

Norgalax has a local effect in the rectum. Minimal absorption cannot be ruled out even with a rectal application.


5.3. Preclinical safety data

Non-clinical data reveal no special hazard for humans based on studies of acute toxicity, repeated dose toxicity and in-vitro genotoxicity. Docusate sodium has been shown to exhibit developmental toxicity in rodents at oral doses that are maternally toxic and sufficiently in excess of the maximum human exposure indicating little relevance to clinical use. High oral doses given during lactation reduced pup weight and survival which was attributed to docusate and its metabolites present in the milk of the dams.


6.1. List of excipients

Glycerol

Sodium carboxymethylcellulose

Purified Water


6.2. Incompatibilities

None known


6.3. Shelf life

3 years


6.4. Special precautions for storage

Do not store above 25°C.


6.5. Nature and contents of container

A polyethylene tube with fixed applicator and a cap closure, containing 10g of gel in pack sizes of 6 and100 tubes.


6.6. Special precautions for disposal and other handling

None.


7. Marketing authorisation holder

Essential Pharma

7 Egham Business Village

Crabtree Road

Egham, Surrey

TW20 8RB

United Kingdom


8. Marketing authorisation number(s)

PL 41871/0007


9. Date of first authorisation/renewal of the authorisation

18/01/2005


10. Date of revision of the text

21/09/2015

4.1 Therapeutic indications

For the symptomatic treatment of constipation whenever an enema is required and for the preparation of the colon and rectum for endoscopic examination.

4.2 Posology and method of administration

Adults: use one micro-enema. If required, a second micro-enema may be used on the same or the next day.

Children:

not recommended for children under 12 years old.

Norgalax is to be administered rectally. Remove the protective cap and insert the applicator in to the rectum, squeezing gently until the tube is empty. A drop of the gel maybe used as a lubricant if required.

4.3 Contraindications

Haemorrhoids, anal fissures, rectocolitis, anal bleeding, abdominal pain, intestinal obstruction, nausea, vomiting, inflammatory bowel disease, ileus and known hypersensitivity to any of the ingredients.

4.4 Special warnings and precautions for use

As with all laxatives, Norgalax should not be administered chronically. Prolonged use can precipitate the onset of an atonic non- functioning colon and hypokalaemia.

4.5 Interaction with other medicinal products and other forms of interaction

Norgalax may increase the resorption of medicines and is not to be used in combination with hepatotoxic agents.

4.6 Fertility, pregnancy and lactation

Pregnancy

There are no adequate data from the use of docusate enema or oral docusate in pregnant women. Animal studies with oral docusate are insufficient with respect to effects on pregnancy and embryonic foetal development.

The potential risk for humans is unknown. As minimal systemic absorption cannot be ruled out following rectal application, Norgalax should be used in pregnancy only if the benefits outweigh the risks.

Lactation

It is unknown whether docusate is excreted in human breast milk. Animal studies have shown excretion of docusate and its metabolites in breast milk when administered systemically. A decision on whether to continue/discontinue breast-feeding or continue/discontinue therapy with NORGALAX should be made taking into account the benefit of breast-feeding to the child and the benefit of NORGALAX therapy to the woman.

4.7 Effects on ability to drive and use machines

None known.

4.8 Undesirable effects

Gastrointestinal disorders: anal burning, rectal pain, rectal bleeding, diarrhoea

Skindisorders: urticaria

Hepaticdisorders: cases of hepatotoxicity have been reported with oral intake of docusate taken together with other laxatives.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard.

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

 

 

Disclaimer

The drug SPC information (indications, contra-indications, interactions, etc), has been developed in collaboration with eMC (www.medicines.org.uk/emc/). Medthority offers the whole library of SPC documents from eMC.

Medthority will not be held liable for explicit or implicit errors, or missing data.

Reporting of suspected adverse reactions 

Drug Licencing

Drugs appearing in this section are approved by UK Medicines & Healthcare Products Regulatory Agency (MHRA), & the European Medicines Agency (EMA).